RO 0506997
Alternative Names: A4I antagonist; RO0506997Latest Information Update: 18 Feb 2014
At a glance
- Originator Roche
 - Class
 - Mechanism of Action Integrin alpha4 inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Discontinued Multiple sclerosis; Rheumatoid arthritis
 
Most Recent Events
- 01 Jan 2008 Discontinued - Phase-II for Multiple sclerosis in Spain (PO)
 - 01 Jan 2008 Discontinued - Phase-II for Rheumatoid arthritis in Spain (PO)
 - 24 Mar 2005 Phase-II clinical trials in Rheumatoid arthritis in Spain (PO)